Transplantation of bone marrow mononuclear cells from polycythemia vera patients into aplastic anemia mice

doi:10.3969/j.issn.2095-4344.2015.23.017

Abstract

Abstract:

BACKGROUND: As the high proliferation and low apoptosis of the bone marrow in polycythemia vera patients, hematopoietic stem cells transplanted into NOD/SCID mice can differentiate into erythroid cells, but whether hematopoietic stem cells transplantation could improve the hematopoietic function of aplastic anemia mice is not yet reported.
OBJECTIVE: To investigate whether transplantation of bone marrow mononuclear cells with JAK2V617F mutation from polycythemia vera patients can influence hematopoietic reconstruction in aplastic anemia mice.
METHODS: Severe aplastic anemia mouse models were established by using recombinant human interferon-γ plus busulfan, and then, these mouse models were randomly divided into experimental group (n=10) and control group (n=10). Bone marrow mononuclear cells isolated from polycythemia vera patients with positive JAK2V617F mutation were transplanted into the mice in the experimental group via tail vein at 5 days after drug withdrawal.
The same volume of normal saline was administered to the control group. Routine peripheral blood test, morphology of bone marrow cells, bone marrow biopsy, and percentage of CD45+ cells in the peripheral blood and marrow were determined at 14 days after transplantation.
RESULTS AND CONCLUSION: At 14 days after transplantation, pancytopenia occurred in the experimental group, bone marrow smears showed scattered lymphocytes and hematopoietic progenitors, and bone marrow biopsy presented that hematopoietic tissues were reduced and a small amount of granulocyte cells and erythroblasts could be seen, but megakaryocytes were rare. In contrast to the control group, there was no improvement in the hematopoietic function of mice in the experimental group. CD45+ cells were detectable in the peripheral blood and bone marrow in the experimental group, but not in the control group; and a higher percentage of CD45+ cells was measured in the bone marrow than in the peripheral blood of experimental group mice. Experimental findings indicate that bone marrow mononuclear cells from polycythemia vera patients with positive JAK2V617F mutation can be engrafted into aplastic anemia mice, but cannot improve the hematopoietic function of mice.

Key words: Bone Marrow Cells, Polycythemia Vera, Anemia, Aplastic, Models, Animal

CLC Number:

R394.2

Zhong Shu-ping, Tian Jing, Liu Xiang, Hou Li-jun, He Zhi-guo, Xu Jing-bo, Li Xue-gang, Xie Feng, Pang Wen-zheng, Liang An-qi. Transplantation of bone marrow mononuclear cells from polycythemia vera patients into aplastic anemia mice[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(23): 3705-3710.

References

[1] Barbui T, Thiele J, Vannucchi AM, et al. Rethinking the diagnostic criteria of polycythemia vera. Leukemia. 2014; 28(6): 1191-1195.

[2] Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507-2513.

[3] Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179-3184.

[4] 白洁,邵宗鸿.真性红细胞增多症造血干及祖细胞生物学特征的研究进展[J].中华内科杂志, 2002,41(2): 140-142.

[5] Pardanani A, Lasho TL, Finke C, et al. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007; 21(9):1960-1963.

[6] Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280(24): 22788-22792.

[7] Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005352(17):1779-1790.

[8] Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397.

[9] James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148.

[10] Wernig G, Mercher T, Okabe R, et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107(11):4274-4281.

[11] Fung TK, Cheung AM, Kwong YL, et al. Differential NOD/SCID mouse engraftment of peripheral blood CD34+ cells and JAK2V617F clones from patients with myeloproliferative neoplasms. Leuk Res. 2010;34(10):1390- 1394.

[12] Pilat N, Wekerle T. Transplantation tolerance through mixed chimerism. Nat Rev Nephrol. 2010;6(10):594-605.

[13] 刘香,钟淑萍,侯丽君,等.重组人γ-干扰素联合白消安诱导建立小鼠重型再生障碍性贫血模型[J].中国组织工程研究, 2014, 18(36): 5868-5873.

[14] Jamieson CH, Gotlib J, Durocher JA, et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A. 2006;103(16):6224-6229.

[15] Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012;120(6):1185-1196.

[16] Chatterjee S, Dutta RK, Basak P, et al. Alteration in marrow stromal microenvironment and apoptosis mechanisms involved in aplastic anemia: an animal model to study the possible disease pathology. Stem Cells Int. 2010;2010: 932354.

[17] Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(5):523-536.

[18] Ten Brink MH, Zwaveling J, Swen JJ, et al. Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics. Drug Discov Today. 2014;19(10): 1572-1586.

[19] 毛平,彭盘俐,许力.人脐血单个核细胞体外扩增后植入NOD/SCID小鼠重建多系造血[J].中华器官移植杂志,2006, 27(4): 231-234.

[20] Marty C, Lacout C, Martin A, et al. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood. 2010;116(5):783-787.

[21] Mullally A, Poveromo L, Schneider RK, et al. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. Blood. 2012;120(1):166-172.

[22] Ishii T, Zhao Y, Sozer S, et al. Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice. Exp Hematol. 2007;35(11):1633-1640.

[23] Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015; 90(2):162-173.